预约演示

Dizal receives approval in China for NSCLC therapy

2023-08-24

上市批准临床结果临床2期CSCO会议申请上市

NSCLC is the most widespread cancer in China. Credit: Egor_Kulinich / Shutterstock.com.

NSCLC has received approval fcancerina’s National Medical Products Administration (NMPA) for sunvozertinib to treat adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion (Exon20ins) mutations.

Sunvozertinib is intended for patients whose disease has advanced on or after platinum-based sunvozertinib locally advanced or metastatic non-small cell lung cancer (NSCLC)

Sunvozertinibeports

ReportsChina Contract Manufacturing Market Outlook - Trends, Ambitions, Key Players, Investment and Valu... GlobalData

ReportsLOA and PTSR Model - TRV-734 in Opium Withdrawal Syndrome GlobalData

View allCompanies IntelligenceNational Medical Products AdministrationView all

Discovered by Dizal scientists, sunvozertinib is an irreversible EGFR inhibitor designed to target a range of EGFR mutations with wild-type EGFR selectivity.

The approval from NMPA was bTRV-734 theOpium Withdrawal Syndromeudy, WU-KONG6, which evaluated sunvozertinib in pretreated NSCLC patients with EGFR Exon20ins mutations.

The trial included 97 patients treated with the recommended Phase II dose of 300mg QD [four times per day].

WU-KONG6’s primary endpoint was sunvozertinibbjective response raEGFR inhibitor EGFRcORR). The resulting rate was 60.8%, a sEGFRficant improvement on currEGFRtreatment options.

Dizal CEO and chairman Xiaolin Zhang stated: “Sunvozertinib represents a groundbreaking achievesunvozertinibirst Chinese inNSCLCive drug approvEGFRor EGFR Exon20ins NSCLC, showcasing Dizal’s remarkable efficiency and unwavering commitment to innovation.

“Our achievement of obtaining NDA approval in less than four years from enrolling the first patient sets an unprecedented benchmark for the rapid development of targeted lung cancer treatments.

“Furthermore, the commercial launch of sunvozertinib represents a significant milestone for Dizal, underscoring our capabilities from research and development to commercialisation.”